ProQR Therapeutics N.V. (PRQR) Issues Earnings Results
ProQR Therapeutics N.V. (NASDAQ:PRQR) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03, Yahoo Finance reports.
Shares of ProQR Therapeutics N.V. (NASDAQ PRQR) remained flat at $$3.10 during midday trading on Tuesday. 75,300 shares of the stock traded hands, compared to its average volume of 69,732. ProQR Therapeutics N.V. has a 12 month low of $2.90 and a 12 month high of $6.90. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.22 and a quick ratio of 8.22.
A number of research analysts have weighed in on PRQR shares. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of ProQR Therapeutics N.V. in a report on Tuesday, September 26th. Zacks Investment Research raised shares of ProQR Therapeutics N.V. from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Tuesday, August 22nd. ValuEngine raised shares of ProQR Therapeutics N.V. from a “sell” rating to a “hold” rating in a report on Friday, September 15th. Chardan Capital reaffirmed a “neutral” rating on shares of ProQR Therapeutics N.V. in a report on Sunday, September 17th. Finally, JMP Securities lifted their price objective on shares of ProQR Therapeutics N.V. from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, September 26th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $19.38.
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.
Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.